Pritchard-Jones K - Search Results

1

Pharmacotherapeutic Management of Wilms Tumor: An Update.

Oostveen RM, Pritchard-Jones K. Oostveen RM, et al. Paediatr Drugs. 2019 Feb;21(1):1-13. doi: 10.1007/s40272-018-0323-z. Paediatr Drugs. 2019. PMID: 30604241 Review.

2

Insulin oedema.

Evans DJ, Pritchard-Jones K, Trotman-Dickenson B. Evans DJ, et al. Postgrad Med J. 1986 Jul;62(729):665-8. doi: 10.1136/pgmj.62.729.665. Postgrad Med J. 1986. PMID: 3529068 Free PMC article.

3

Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.

Williams RD, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, Little S, Hing SN, Fenwick K, Ashworth A, Grundy P, Anderson JR, Dome JS, Perlman EJ, Jones C, Pritchard-Jones K. Williams RD, et al. Genes Chromosomes Cancer. 2011 Dec;50(12):982-95. doi: 10.1002/gcc.20907. Epub 2011 Aug 31. Genes Chromosomes Cancer. 2011. PMID: 21882282

4

Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial.

Pritchard-Jones K, Moroz V, Vujanić G, Powis M, Walker J, Messahel B, Hobson R, Levitt G, Kelsey A, Mitchell C. Pritchard-Jones K, et al. Ann Oncol. 2012 Sep;23(9):2457-2463. doi: 10.1093/annonc/mds025. Epub 2012 Mar 13. Ann Oncol. 2012. PMID: 22415585 Free article.

5

Bilateral wilms tumor with TP53-related anaplasia.

Popov SD, Vujanic GM, Sebire NJ, Chagtai T, Williams R, Vaidya S, Pritchard-Jones K. Popov SD, et al. Pediatr Dev Pathol. 2013 May-Jun;16(3):217-23. doi: 10.2350/12-08-1245-CR.1. Epub 2013 Feb 6. Pediatr Dev Pathol. 2013. PMID: 23387809

6

Is Wilms tumor a candidate neoplasia for treatment with WNT/β-catenin pathway modulators?--A report from the renal tumors biology-driven drug development workshop.

Perotti D, Hohenstein P, Bongarzone I, Maschietto M, Weeks M, Radice P, Pritchard-Jones K. Perotti D, et al. Mol Cancer Ther. 2013 Dec;12(12):2619-27. doi: 10.1158/1535-7163.MCT-13-0335. Epub 2013 Nov 20. Mol Cancer Ther. 2013. PMID: 24258344 Free PMC article. Review.

7

TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.

Maschietto M, Williams RD, Chagtai T, Popov SD, Sebire NJ, Vujanic G, Perlman E, Anderson JR, Grundy P, Dome JS, Pritchard-Jones K. Maschietto M, et al. PLoS One. 2014 Oct 14;9(10):e109924. doi: 10.1371/journal.pone.0109924. eCollection 2014. PLoS One. 2014. PMID: 25313908 Free PMC article.

8

The yin and yang of kidney development and Wilms' tumors.

Hohenstein P, Pritchard-Jones K, Charlton J. Hohenstein P, et al. Genes Dev. 2015 Mar 1;29(5):467-82. doi: 10.1101/gad.256396.114. Genes Dev. 2015. PMID: 25737276 Free PMC article. Review.

9

Multiple mechanisms of MYCN dysregulation in Wilms tumour.

Williams RD, Chagtai T, Alcaide-German M, Apps J, Wegert J, Popov S, Vujanic G, van Tinteren H, van den Heuvel-Eibrink MM, Kool M, de Kraker J, Gisselsson D, Graf N, Gessler M, Pritchard-Jones K. Williams RD, et al. Oncotarget. 2015 Mar 30;6(9):7232-43. doi: 10.18632/oncotarget.3377. Oncotarget. 2015. PMID: 25749049 Free PMC article.

10

A multi-Gaussian model for apparent diffusion coefficient histogram analysis of Wilms' tumour subtype and response to chemotherapy.

Hales PW, Olsen ØE, Sebire NJ, Pritchard-Jones K, Clark CA. Hales PW, et al. NMR Biomed. 2015 Aug;28(8):948-57. doi: 10.1002/nbm.3337. Epub 2015 Jun 9. NMR Biomed. 2015. PMID: 26058670 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

337 results

Search Page

Filters